WO2009037723A1 - Procédé pour la génération et l'expansion de lymphocytes t régulateurs gamma/delta, cellules ainsi obtenues et leurs utilisations - Google Patents

Procédé pour la génération et l'expansion de lymphocytes t régulateurs gamma/delta, cellules ainsi obtenues et leurs utilisations Download PDF

Info

Publication number
WO2009037723A1
WO2009037723A1 PCT/IT2008/000544 IT2008000544W WO2009037723A1 WO 2009037723 A1 WO2009037723 A1 WO 2009037723A1 IT 2008000544 W IT2008000544 W IT 2008000544W WO 2009037723 A1 WO2009037723 A1 WO 2009037723A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
lymphocytes
cell cultures
treg
foxp3
Prior art date
Application number
PCT/IT2008/000544
Other languages
English (en)
Inventor
Rita Casetti
Chiara Agrati
Alessandra Sacchi
Federico Martini
Alessandra Rinaldi
Fabrizio Poccia
Original Assignee
Istituto Nazionale Per Le Malattie Infettive
Costa, Cristina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale Per Le Malattie Infettive, Costa, Cristina filed Critical Istituto Nazionale Per Le Malattie Infettive
Publication of WO2009037723A1 publication Critical patent/WO2009037723A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Definitions

  • the present invention relates to an in- ⁇ itro process for the generation and expansion of ⁇ T regulatory cells ( ⁇ Treg cells) that express the transcription factor Foxp3 starting from a sample of peripheral blood mononuclear cells (PBMCs).
  • ⁇ Treg cells thus generated are used to induce a potent in- ⁇ itro inhibition of the proliferation of ⁇ T lymphocytes in man.
  • the regulatory capacity of the cells obtained by the method according to the invention can be exploited in the treatment of autoimmune diseases, for the prevention of transplant rejection, and, in general, in the treatment of clinical frames that benefit from negative modulation of the immune response.
  • TCR the T cell receptor
  • TCR is a dimeric membrane protein of T lymphocytes that presents a portion of its own structure on the outer surface of these cells.
  • TCR consists, in approximately 95% of lymphocytes, of a heterodimer comprising an ⁇ chain and a ⁇ chain ( ⁇ T lymphocytes), whereas in the remaining portion of the lymphocyte population it consists of a heterodimer comprising a ⁇ and a ⁇ protein chain ( ⁇ T lymphocytes).
  • the function of the TCR consists in recognising antigens bound to MHC (Major Histocompatibility Complex) molecules on the cell surface. The TCR recognizes the antigen only in the context of MHC molecules.
  • MHC Major Histocompatibility Complex
  • Foxp3 is a nuclear transcription factor responsible for the suppression of the proliferation of ⁇ T lymphocytes. It acts by inhibiting the transcription of IL.-2 and increasing the expression of factors that suppress immune responses.
  • Treg the T regulatory cells known until now the ⁇ receptor and are characterised as described below.
  • nTreg cells are natural regulatory cells which originate in the thymus and constitutively express Foxp3. Their function is to inhibit the proliferation and production of cytokines by T lymphocytes in the course of the immune response once the pathogen has been eliminated. It has been demonstrated that they are responsible for the control of autoimmune diseases in that they inhibit the lymphocytes activated pathologically against autoantigens.
  • nTreg cells are represented by the T lymphocytes CD4/CD25 hi s h , have a very low proliferative capacity in vitro and require the presence of exogenous IL- 2 to exert their suppressive activity. To perform their function they also need stimulation of the TCR and cell-to-cell contact (Paust S. and Cantor H. (2005) Immunol. Rev. 204, 195-207; Baecher-Allan C. and Hafler D.A. (2006) Immunol. Rev. 212, 203-216).
  • - iTreg cells these are induced adaptive regulatory cells. These cells derive from the T lymphocytes CD4 + /CD25" which, in the presence of IL-2, IL- 15 and TGF- ⁇ , differentiate into CD25 + regulatory cells that express Foxp3, secrete TGF- ⁇ and are capable of inhibiting the proliferation and production of cytokines of non-stimulated T lymphocytes with a mechanism independent of contact. These cells show a phenotype similar to the natural regulatory cells but the Foxp3 expression is transient and requires the continuous presence of IL-2 and TGF- ⁇ in the culture medium (Ramesh K., et al. Journal of Immunology (2007) 178: 7667-7677).
  • TrI cells are regulatory cells induced following repeated in- ⁇ itro stimulations of human CD4 + lymphocytes in the presence of IL- 10. TrI cells inhibit the T cell-mediated response to pathogens, alloantigens and cancer cells. TrI cells have a very low proliferative ability and their suppressive capacity is mediated by soluble factors, particularly IL-10. They do not express Foxp3.
  • - Th3 cells these cells constitute the only subgroup of regulatory cells that are induced by antigens introduced into the oral cavity with food. Their suppressive ability is not based on direct cell contact but is mediated by TGF- ⁇ . They do not express Foxp3.
  • CD8 + CD28 cells these cells suppress the immune response in a manner dependent upon contact between cells, interacting directly with APCs (Antigen Presenting Cells) and rendering the latter tolerogenic.
  • APCs Antigen Presenting Cells
  • APCs are defined as tolerogenic when, as a result of lack of expression of particular surface proteins, their interaction with the cells of the immune system induces a block of their proliferation instead of activation, as normally occurs.
  • ⁇ T lymphocytes These express the ⁇ heterodimer of the TCR on their surface. They comprise CD4 and CD8 T lymphocytes. They take part in specific immunity and expand as a result of contacting the specific peptide antigen, presented in the context of MHC molecules by specialised cells. They can exhibit both direct cytostatic activity (CD8 + T lymphocytes) on the target cells (for example, cells containing a pathogenic agent or tumour cells) and a support activity (CD4 helper cells) or inhibitory activity (CD4 Treg cells) in the specific immune response.
  • CD8 + T lymphocytes on the target cells (for example, cells containing a pathogenic agent or tumour cells) and a support activity (CD4 helper cells) or inhibitory activity (CD4 Treg cells) in the specific immune response.
  • ⁇ lymphocytes these are T lymphocytes that express the ⁇ heterodimer of the TCR. Unlike the ⁇ T lymphocytes, they recognise non-peptide antigens via a mechanism independent of presentation by MHC molecules (Bukowsky J.F. J. Immunol. (1995) 154: 998; Morita C. T. Immunity. (1995) 3: 495). In man, two populations of ⁇ T lymphocytes are present:
  • V ⁇ 9V ⁇ 2 T lymphocytes are involved in the immune response against intracellular pathogens and haematological diseases (Poccia F. et al. Immunol. Today, 1998, 19:253; Poccia et al. Curr. MoI. Med. 2001, 1: 137; Ferrarini M. et al. Trends Immunol. 2002, 23: 14).
  • the homeostasis of the immune system depends on the equilibrium between the response to an invading pathogen and the tolerance of the immune system to autoantigens.
  • This equilibrium is achieved by rigid selection at the thymus level, by means of which the T lymphocytes with TCR specific for self antigens are eliminated, whereas all the others, capable of recognising foreign antigens, migrate into the lymph nodes at peripheral level, where the contact with the possible pathogen may take place. Not all the autoreactive T lymphocytes, however, are eliminated in this phase, and those that escape this selection enter the bloodstream. At the peripheral level these potentially autoreactive clones are inhibited thanks to the presence of ⁇ CD4 + regulatory cells.
  • the CD4 + regulatory cells in turn, also have the function of suppressing the immune response to a pathogen, when the latter has been eliminated, avoiding the possibility of tissue damage due to an excessive immune response.
  • ⁇ T lymphocytes reactive against autoantigens damage the tissues and organs, causing major clinical damage, as in the case of type I diabetes or autoimmune thyroiditis.
  • CD4 and CD8 T lymphocytes which have escaped the negative selection of the autoreactive clones at thymus level are capable of exerting a potentially pathogenic autoreactive response.
  • T regulatory lymphocytes (T regulatory cells, Treg) play a very significant role in the induction and maintenance of tolerance on the part of the other T lymphocytes. They are responsible, in fact, for the limitation of the immune response and for the inhibition of induction of autoimmunity (Sakaguchi, S. (2004) Ann. Rev. Immunol. 22, 531).
  • Treg cells have so far been identified as T lymphocytes that express the ⁇ heterodimer of the TCR and the molecules CD4+CD25 hi e h (Paust S. and Cantor H. (2005) Immunol. Rev. 204, 195-207; Baecher-Allan C. and Hafler D.A. (2006) Immunol. Rev. 212, 203-216). From recent studies it has emerged that these Treg cells specifically express the nuclear transcription factor Foxp3. It would appear that Foxp3 is the main gene controlling the development and function of Treg cells (nTreg and iTreg) and to date the protein is considered the best molecule to identify these cells (L.A. Schubert, et al. J. Biol. Chem.
  • T cells that are capable of inhibiting the proliferation of ⁇ T cells, such as the type 1 regulatory cells (TrI) that produce IL-10 and the Th3 cells that produce TGF- ⁇ , never express the protein Foxp3.
  • TrI type 1 regulatory cells
  • nTreg Foxp3 + cells The mechanism of action is different for the various subtypes of Treg Foxp3 + .
  • the inhibitory activity of nTreg Foxp3 + cells is based on a mechanism independent of cytokines, i.e. it does not involve the action of cytokines with a suppressive function, such as IL-4, IL-10 and TGF- ⁇ 1, but needs cell-to-cell contact.
  • a suppressive function such as IL-4, IL-10 and TGF- ⁇ 1
  • Treg cells we have no detailed knowledge of the functional mechanism used by Treg cells to inhibit the response of CD4 or CD8 effector cells either in vitro or in vivo, though various authors have done a great deal of work in the field (Thornton A.M., Shevach E.M. J. Exp. Med. (1998) 188: 287; Thornton A.M. et al. J. Immunol (2004) 172: 6519; Jonuleit H. et al. J. Exp. Med. (2002) 196: 255).
  • autoimmune diseases Two hypotheses have been formulated as to the origin of autoimmune diseases. According to the first one, such diseases depend upon a reduced number or reduced function of regulatory cells.
  • the second hypothesis postulates that autoimmune diseases are the consequence of the development of pathogenic T cells resistant to regulation.
  • the regulatory cells control the progression of the disease by inhibiting the activation of effector cells and their function: nevertheless, effector cells resistant to regulation may accumulate over time, giving rise to onset of the disease (Tang Q. and Bluestone JA. Immunological Review (2006) 212: 217).
  • Treg cells inhibit the proliferation of other T cells, blocking the production of IL- 2.
  • In- ⁇ ivo studies suggest lastly that the regulatory cells control various aspects of the immune response including proliferation, production of cytokines, migration towards target tissues and the effector functions of the cells present in the tissue concerned.
  • any organ within the cardiocirculatory system, the digestive tract, the visual system, the endocrine system, the skin, joints, kidneys and lungs, the muscular system and the nervous system can be affected by an autoimmune disease (NIH Publication No.02 4858, (2002) "Questions and answers about autoimmunity").
  • autoimmune diseases depends considerably on the type of organ affected, on the severity of the disease and on its symptoms.
  • the general clinical approach to this class of diseases aims at reducing the symptoms (which may include the prescription of analgesic drugs or extend even to the removal of the part affected), at preserving the functions of the organ affected (for example, by using anti-inflammatory drugs such as corticosteroids or hormone replacement therapies) and at reducing the general immune response (for example, by means of therapy with immunosuppressors such as cyclosporin and cyclophosphamide).
  • anti-inflammatory drugs such as corticosteroids or hormone replacement therapies
  • immunosuppressors such as cyclosporin and cyclophosphamide
  • CD4 regulatory cells Another important function of CD4 regulatory cells is that of being potent inhibitors of effector functions following organ transplantation. Recognition of alloantigens by CD4 T lymphocytes leads to the expansion not only of antigen-specific effector cells with pathogenic effects but also of antigen-specific CD4 regulatory cells, which can inhibit transplant rejection in an antigen-specific manner. Studies are in progress to apply this tolerogenic capacity to organ transplantation, particularly when a reduced tissue compatibility would lead for sure to rejection. (Boschiero L. et al., Transplantation Proceedings 2007; 39:2013-2017).
  • ⁇ T lymphocytes also play an important role in regulating the early inflammatory response to microbial infections and thus in preventing excessive tissue damage (Fu Y. -X. et al. J. Immunol. (1994) 153: 3101; King D. P. et al. J. Immunol. (1999) 162: 5033; Egan P.J. et al. J. Exp. Med. (2000) 191: 2145; Skeen M.J. et al. Infect. Immun. (2001) 69: 7213; Skeen M.J. et al. J. Leukoc. Biol. (2004) 76: 104; Tagawa T. et al. J. Immunol. (2004) 173: 5156).
  • ⁇ T lymphocytes perform their regulatory function by influencing the chemotaxis and function of effector cells that play a key role in inflammation, such as neutrophils (Fu Y.-X. et al. J Immunol. (1994) 153: 3101; D'Souza CD. et al. J. Immunol. (1997) 158: 1217), macrophages (Egan P.J. et al. J. Exp. Med. (2000) 191: 2145; Tagawa T. et al. J Immunol. (2004) 173: 5156), and NK cells (Li B. et al. J. Immunol. (1998) 161 1558; Vincent M.S. et al. J. Exp. Med. (1996) 184: 2109).
  • the cells that express the ⁇ receptor recognise non-protein antigens in a manner not restricted to MHC very early in the course of an infection, they are considered part of the first line of defence of the host.
  • the resemblance of the pathogenic antigens recognised by the ⁇ T lymphocytes to the molecules expressed by the host's damaged cells suggests that the responses of the ⁇ T lymphocytes are induced more by non-specific molecules of damaged cells than by the excessive presence of microbial antigens or foreign antigens (Hayday A.C. Ann. Rev. Immunol. (2000) 18: 975).
  • ⁇ T lymphocytes may lead to the production of IFN ⁇ , essential in the activation of macrophages and NK cells, which are important in the early antibacterial protection before the specific response of the ⁇ T cells is activated (see Hayday A. C. above)
  • Methods are known for expanding ⁇ T cells in vitro starting from PBMCs by stimulation with phosphorylated compounds of bacterial origin containing nucleotides or by means of isoprenoid pyrophosphates such as isopentenyl pyrophosphate (IPP) in the presence of cytokines, such as IL-2 and IL-15 (WO 03/070921), for the purposes of obtaining a large number of ⁇ T cells that can be used in the course of infectious diseases and tumours utilising the known effector functions, for example, the cytotoxicity and the adaptive response induction function of ⁇ cells by means of cytokines, for stimulating and thus increasing the immune defences of the subject treated.
  • IPP isopentenyl pyrophosphate
  • cytokines such as IL-2 and IL-15
  • ⁇ T cells Nevertheless, though many studies have been conducted on the functions of ⁇ T cells, no evidence has been found among these cells for the possible existence of a subpopulation of ⁇ T cells with a function comparable to that of the ⁇ Treg cells or which can be characterised by expression of the Foxp3 transcription factor and having the function of suppressing the response of other activated T lymphocytes.
  • ⁇ Treg cells possess the ability to inhibit the replication of ⁇ . cells.
  • the method is based on the stimulation of lymphocytes with a specific antigen for V ⁇ 9V ⁇ 2 T lymphocytes such as isopentenyl pyrophosphate (IPP), in the presence of cytokines, such as interleukin-2 (IL-2) and interleukin-15 (IL- 15) and a growth factor such as Transforming Growth Factor ⁇ -1 (TGF- ⁇ l).
  • IPP isopentenyl pyrophosphate
  • cytokines such as interleukin-2 (IL-2) and interleukin-15 (IL- 15)
  • TGF- ⁇ l Transforming Growth Factor ⁇ -1
  • One subject of the invention is therefore a process for the production of ⁇ Treg cells that comprises:
  • peripheral blood mononuclear cells should preferably derive from cytapheresis.
  • the cells used are preferably human and may come from frozen biological samples.
  • Another object of the invention resides in that the cell cultures obtained with the process according to the invention, characterised by the fact that they contain, in the context of the ⁇ T cell population, at least 30% of ⁇ Treg cells expressing the protein Foxp3.
  • Anadditional object of the invention resides in the subpopulation of V ⁇ 9V ⁇ 2 T regulatory cells with the characteristics described here below.
  • a further object of the invention resides in pharmaceutical compositions characterised in that they contain a population of ⁇ T cells in which at least 30% consist of ⁇ T regulatory cells expressing Foxp3.
  • the compositions additionally contain a pharmaceutically acceptable vehicle such as a stabilising agent, for example, human serum albumin.
  • Yet a further object of the present invention resides in the use of the subpopulation of said ⁇ T regulatory cells expressing Foxp3 for pharmaceutical, therapeutic, experimental, cosmetic and research purposes, with particular reference to clinical frames that benefit from negative modulation of the immune response, such as, for example, autoimmune diseases and the prevention of transplant rejection.
  • the in-vitro method according to the invention makes it possible to generate, starting from a biological sample, generally a sample of peripheral blood mononuclear cells (PBMCs), a particular subpopulation of ⁇ T cells, i.e. V ⁇ 9V ⁇ 2 cells, with regulatory activity which, as well as expressing the Foxp3 nuclear transcription factor, present the following additional characteristics: a. they express the following surface markers: CD25, CTLA-4, CD 127, CD45RO, CD69, and CD27; b. they exert a regulatory capacity in that they inhibit the proliferation of ⁇ T lymphocytes; c.
  • PBMCs peripheral blood mononuclear cells
  • ⁇ lymphocytes does not require cell-to-cell contact but is mediated by one or more soluble factors, in that it is also exerted when the two cell populations ( ⁇ Treg cells and stimulated PBMCs) are separated by a porous membrane that does not allow the passage of cells but only of the soluble factors produced by them (experiment not shown); d. they are capable of influencing the differentiation and maturation of dendritic cells, modulating the expression of a number of molecules typical of differentiated and/or mature dendritic cells (CD80, CD86) (experiment not shown).
  • the ⁇ Treg cells that are obtained with the method according to the invention are CD4 and CD8 negative cells since they derive from ⁇ T lymphocytes that normally do not express these markers. Furthermore, the cells according to the invention are all positive for the proteins CD25 and CTLA-4, which are typical markers of activated leukocytes.
  • the ⁇ Treg cells that are obtained by means of the method according to the invention are also all positive for the activation marker CD 127.
  • CD 127 is a protein normally expressed on all human T cells and one whose presence is regulated negatively as a result of activation of T lymphocytes. In ⁇ Treg cells, which by definition express Foxp3, the presence of the protein CD 127 would appear to remain constantly suppressed precisely as a result of the Foxp3 action (Weihong L. et al. J Exp Med (2006) 203; 1701).
  • the presence of CD 127 on the ⁇ Treg cells obtained by the method according to the invention is therefore a further feture that differentiates them from the Treg cells studied up to
  • ⁇ Treg cells A fundamental characteristic of ⁇ Treg cells that differentiates them from CD4 regulatory cells is also the fact that the suppressive function of ⁇ Treg cells is not antigen-specific, unlike other cells, which in contrast exert their action only following recognition of a specific antigen in the context of the major histocompatibility complex.
  • the advantage might be that a more extensive suppressive activity is obtained, and one applicable regardless of the specificity of the immune response that has to be inhibited.
  • the lack of antigen specificity is the main advantage of ⁇ cells over the corresponding ⁇ cells.
  • the method according to the invention for the preparation of a composition of cells including ⁇ Treg cells expressing Foxp3 comprises the following steps:
  • stage (ii) recover the cells thus obtained, for example, by cytofluorimetric separation, e.g. with a FACS-Vantage, FACS-Aria Flow Cytometer (Becton Dickinson) or the like, or by means of immunomagnetic methods (Molday RS, Yen SP, Rembaum A. Nature (1977) 268:437).
  • the biological preparation of stage (i) is generally a sample of lymphocytes obtained, for example, by purification of PBMCs starting from a normal sample of peripheral blood or by cytapheresis, also thawed.
  • the PBMCs from peripheral blood are preferably isolated by means of the Ficoll-Hypaque technique according to methods with which experts in the field are familiar.
  • the blood is stratified on a density gradient (Ficoll-Hypaque) and, by means of centrifuging, the mononuclear cells form a ring (buffy coat) which is easily collected and used.
  • the lymphocytes present in the buffy coat are cultured in suitable medium selected from those available on the market, for example, RPMI 1640 complete medium containing 10% heat-inactivated FBS (Foetal Bovine Serum), penicillin/streptomycin and 1-glutamine, in the presence of cytokines, proliferation activators and growth factors.
  • suitable medium selected from those available on the market, for example, RPMI 1640 complete medium containing 10% heat-inactivated FBS (Foetal Bovine Serum), penicillin/streptomycin and 1-glutamine, in the presence of cytokines, proliferation activators and growth factors.
  • the cytokines in particular are interleukins, and more particularly IL- 2, preferably usable* at a concentration of approximately 20-100 U /ml, and IL- 15, preferably usable at a concentration of approximately 2500- 6500 U/ml, and mixtures thereof.
  • the growth factor belongs to the TGF- ⁇ (Transforming Growth Factor ⁇ ) family, and an be used at a concentration ranging from approximately 0.5 ng/ml to 2.5 ng/ml. It can be of human or animal origin, preferably human. Particularly preferred is TGF- ⁇ 1.
  • TGF- ⁇ Transforming Growth Factor ⁇
  • also natural or synthetic variants of growth factors can be used, where what is meant by variants are the polypeptide chains which, by mutation, deletion, substitution and/or addition of one or more amino acids, conserve the ability to generate ⁇ Treg cells expressing Foxp3.
  • the synthetic activator is a specific compound for the proliferation of ⁇ , T lymphocytes, for example, it is a phosphoantigen selected from among those described in WO95/20673; particularly preferred is IPP (US5639653), used at a concentration ranging from 10 ⁇ g/ml to 50 ⁇ g/ml. It is present only in the initial stage of culture to trigger the proliferation.
  • the lymphocytes are advantageously cultured initially in the presence of activator, cytokines and growth factors for at least three days, preferably for a period ranging from 3 to 10 days at 37°C. Every three days half of the spent culture medium is replaced by the same medium, but without the specific synthetic activator, for a period of time typically ranging from 3 to 30 days.
  • the subpopulation of ⁇ Treg cells obtained by means of the method according to the invention can be used at the time of preparation, can be placed in cytapheresis bags, or can be stabilised for storage according to methods with which the expert in the field is familiar, possibly by cryopreservation.
  • the cells are maintained in a medium containing a stabilising agent such as a polymer or a particular neutral protein.
  • a stabilising agent such as a polymer or a particular neutral protein.
  • HSA human serum albumin
  • the cells obtained with the method according to the invention can be combined in a pharmaceutical composition additionally containing pharmaceutically acceptable carriers, vehicles, stabilising agents, preservatives and excipients which in themselves are known to the expert in the field.
  • These compositions can be formulated in liquid form for parenteral use and can be prepared for the purposes of simultaneous, separate or temporally spaced use, possibly in combination with other pharmacological treatments.
  • the methods of application/administration of the cells according to the invention can differ according to the type of use and depend on the particular therapeutic model implemented.
  • a preventive treatment of the organ to be transplanted with inhibitory T regulatory cells obtained from PBMCs is advisable, preferably but not necessarily, from the recipient, so as to induce a state of tolerance confined only to the transplanted tissue site, without modifying in any way the systemic immunological competence.
  • the treatment might consist in placing the organ to be treated, or suitably removed from its natural site, in contact with an effective amount of a culture of ⁇ Treg cells expressing Foxp3 for a period sufficient to prevent rejection of the organ once transplanted.
  • the cell populations according to the invention can be used in the preparation of pharmaceutical compositions for modulating the immune defences in patients suffering from autoimmune diseases in order to limit the damage caused by an excessive or abnormal response of the immune system.
  • Any organ within the cardiocirculatory system, the digestive tract, the visual system, the endocrine system, the skin, joints, kidneys and lungs, the muscular system and the nervous system can be affected by an autoimmune disease (NIH Publication No. 02 4858, (2002) "Questions and answers about autoimmunity").
  • Treg infusional therapy can be administered in combination with traditional immunosuppressive pharmacological therapies.
  • immunosuppressive drugs with a consequent reduction' in side effects, to the point where the immunosuppressive therapy can be totally eliminated as a result of successful achievement of a state of acquired immune tolerance.
  • the advantages over therapy with ⁇ / ⁇ Treg cells are the greater number of cells obtainable by means of the expansion in vitro, greater efficacy depending upon the greater permanence of the Foxp3 marker on the ⁇ Treg cells and their ability to act regardless of the antigen specificity of the response to be inhibited.
  • Example 1 In- vitro generation of ⁇ Tree cells.
  • the lymphocytes were isolated from buffy coats of healthy donors by means of the Ficoll-Hypaque technique (Pharmacia, Uppsala, Sweden) as described above, and were cultured at a concentration of 4xlO 6 cells/ml in complete medium (RPMI 1640 with 10% heat-inactivated FBS, 2 mM 1-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin) in the presence of interleukin-2 (IL-2, 100 U/ml), interleukin-15 (IL-15, 4500 U/ml), Transforming Growth Factor- ⁇ l (TGF- ⁇ l, 1.7 ng/ml) and a specific stimulus for V ⁇ 9V ⁇ 2 T lymphocytes, such as isopentenyl pyrophosphate (IPP, 20 ⁇ g/ml).
  • IPP isopentenyl pyrophosphate
  • ⁇ Treg cells On day three, half the culture medium was replaced by fresh medium and the cytokines and growth factor were added again. On day four, the induction of ⁇ Treg cells was evaluated. The cells were washed with PBS buffer containing 1% BSA and 0.1% sodium azide and incubated for 15 minutes at 4°C with the following monoclonal antibodies to human proteins: anti-V ⁇ 2 conjugated with FITC; anti-CD25 conjugated with PE-C5 and anti- CD 127 conjugated with APC. Intracellular staining with antibody to human protein FoxP3 conjugated with PE was later performed.
  • FIGS. IA and IB illustrate the results of the cytofluorimetric analysis on human leukocytes after 4 days in culture in the presence and in the absence of the stimulating agents according to the invention, suitable for generating ⁇ Treg cells expressing the Foxp3 transcription factor.
  • the result is expressed as the amount of ⁇ T cells expressing Foxp3 ex vivo (i.e.
  • FIG. 1B shows the respective graphic representation of the results of the cytofluorimetric analysis in the different conditions described above.
  • Example 2 Phenotvpic analysis of ⁇ Treg cells.
  • the ⁇ Treg lymphocytes were analysed phenotypically with a flow cytometer using the following conjugated antibodies and fluorochromes: anti-V ⁇ 2-FITC, anti-CD4-FITC, anti-Foxp3-PE, anti- CD3-PerCP, anti-CD25-PECy5, anti-CD 127-APC, anti-CD27-PC5, anti-CD45RA-APC, anti-CTLA-4-PE, anti-CD45RO-APC, CD69-APC.
  • Figure 2 illustrates the phenotypic characterisation of the ⁇ Treg lymphocytes by means of cytofluorimetric analysis. It should be noted that the median peak fluorescence for the different markers (indicated in the figure) is greater in the ⁇ T cells according to the invention which also express the Foxp3 factor (top panel) than in the ⁇ T cells that do not express it (bottom panel).
  • the expression of Foxp3 was evaluated as follows. Peripheral blood mononuclear cells, stimulated for 4 days with IL-2, IL- 15 and TGF- ⁇ in the presence of IPP, were first labelled with a specific fluoresecent antibody for the surface molecule V ⁇ 2, which identifies lymphocytes with TCR V ⁇ 9V ⁇ 2 and were subsequently labelled with a monoclonal antibody (BioLegend) with a different fluorescence than the previous one, specific for the cytoplasmic transcription factor Foxp3 according to the manufacturer's instructions. In short, the cells were fixed in Fix/Perm Buffer and incubated at room temperature in the dark for 15 minutes.
  • the cells were then washed and permeabilised with Perm Buffer and incubated at room temperature in the dark for 10 minutes. Subsequently, in appropriate test tubes, the anti-Foxp3 monoclonal antibody conjugated with PE or the human anti-IgG control antibody, isotype k, conjugated with PE was added and the cells were incubated in the dark for 20 minutes.
  • the cells thus labelled were acquired with a FACScalibur Flow Cytometer and the percentage of cells with the V ⁇ 9V ⁇ 2 receptor expressing Foxp3 was analysed using CellQuest software (Bekyon Dickinson Immunocytometry Systems).
  • the antiproliferative capacity of the ⁇ Treg cells was measured by the method using Carboxyfluorescein Diacetate, Succinimidyl Ester (CFDA, SE), a fluorescent intracytoplasmic label whose intracellular concentration is halved at every cell division. This halving is measured cytofluorimetrically as peaks with a decreasing fluorescence intensity which represent the cells that have undergone one or more cell divisions.
  • CFDA Carboxyfluorescein Diacetate, Succinimidyl Ester
  • FIG. 3 shows the results of the proliferation inhibition experiment described above.
  • the peaks on the right in the respective profiles represent the labelled ⁇ cells that have not proliferated.
  • the intermediate peaks and those on the left in the respective profiles represent the labelled ⁇ cells that have proliferated and therefore show an increasingly less intense fluorescence.
  • ⁇ Treg cells obtained by the method according to the invention that express Foxp3 ( ⁇ Treg) are capable of inhibiting the proliferation of the stimulated ⁇ T lymphocytes (profile No. 4).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé in-vitro pour la génération et l'expansion de lymphocytes T régulateurs γδ qui expriment le facteur de transcription Foxp3 (lymphocytes T régulateurs γδ), à partir de la culture de cellules mononucléaires sanguines périphériques (PBMC) en présence de cytokines, telles que l'IL-2, l'IL-15, de facteurs de croissance et d'antigènes activateurs spécifiques. L'invention concerne également l'utilisation de lymphocytes T régulateurs γδ pour le traitement dans des cadres cliniques qui tirent un avantage de la modulation négative de la réponse immunitaire.
PCT/IT2008/000544 2007-08-10 2008-08-08 Procédé pour la génération et l'expansion de lymphocytes t régulateurs gamma/delta, cellules ainsi obtenues et leurs utilisations WO2009037723A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2007A000437 2007-08-10
IT000437A ITRM20070437A1 (it) 2007-08-10 2007-08-10 Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi

Publications (1)

Publication Number Publication Date
WO2009037723A1 true WO2009037723A1 (fr) 2009-03-26

Family

ID=40149739

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2008/000544 WO2009037723A1 (fr) 2007-08-10 2008-08-08 Procédé pour la génération et l'expansion de lymphocytes t régulateurs gamma/delta, cellules ainsi obtenues et leurs utilisations

Country Status (2)

Country Link
IT (1) ITRM20070437A1 (fr)
WO (1) WO2009037723A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110158954A1 (en) * 2007-03-09 2011-06-30 Mitsuko Ideno Method for producing gamma delta t cell population
WO2012131419A1 (fr) 2011-03-25 2012-10-04 Txcell Méthode d'utilisation des lymphocytes t régulateurs en thérapie
WO2014072446A1 (fr) * 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour induire la prolifération sans il-2 de lymphocytes t gamma delta
WO2015035063A3 (fr) * 2013-09-05 2015-11-05 Sanford-Burnham Medical Research Institute Modulation des lymphocytes t (γδ)
CN107208061A (zh) * 2014-12-05 2017-09-26 伦敦国王学院 γδ T细胞扩增方法
WO2018024896A1 (fr) * 2016-08-05 2018-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) GÉNÉRATION EX VIVO DE LYMPHOCYTES T RÉGULATEURS γδ FOXP3+ ET UTILISATIONS THÉRAPEUTIQUES CORRESPONDANTES
JP2019530470A (ja) * 2016-08-05 2019-10-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＦｏｘｐ３＋調節性Ｔ細胞のエクスビボ生成及びその治療的使用
CN113105550A (zh) * 2014-04-10 2021-07-13 拉法医疗有限公司 结合人Vγ9Vδ2 T细胞受体的免疫球蛋白
JP2022515791A (ja) * 2018-12-24 2022-02-22 ▲広▼▲東▼▲ジ▼▲徳▼康民生物科技有限▲責▼任公司 ヒトＶγ９Ｖδ２Ｔ細胞増殖培養方法及び培地
US11384336B2 (en) 2016-12-07 2022-07-12 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
WO2003059264A2 (fr) * 2001-12-21 2003-07-24 University Of Southern California Procedes d'induction de lymphocytes t regulateurs professionnels et des lymphocytes t produisant des cytokines
WO2003070921A1 (fr) * 2002-02-22 2003-08-28 Innate Pharma PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES ϜδT
WO2006127152A2 (fr) * 2005-04-05 2006-11-30 University Of Southern California Procedes de production et d'utilisation de lymphocytes t regulateurs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639653A (en) * 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
WO2003059264A2 (fr) * 2001-12-21 2003-07-24 University Of Southern California Procedes d'induction de lymphocytes t regulateurs professionnels et des lymphocytes t produisant des cytokines
WO2003070921A1 (fr) * 2002-02-22 2003-08-28 Innate Pharma PROCÉDÉS DE PRODUCTION DE LYMPHOCYTES ϜδT
WO2006127152A2 (fr) * 2005-04-05 2006-11-30 University Of Southern California Procedes de production et d'utilisation de lymphocytes t regulateurs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PENG YULFENG ET AL: "TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 13, 30 March 2004 (2004-03-30), pages 4572 - 4577, XP002509587, ISSN: 0027-8424 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110158954A1 (en) * 2007-03-09 2011-06-30 Mitsuko Ideno Method for producing gamma delta t cell population
WO2012131419A1 (fr) 2011-03-25 2012-10-04 Txcell Méthode d'utilisation des lymphocytes t régulateurs en thérapie
WO2014072446A1 (fr) * 2012-11-08 2014-05-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour induire la prolifération sans il-2 de lymphocytes t gamma delta
JP2016501013A (ja) * 2012-11-08 2016-01-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＴ細胞の無ＩＬ−２増殖を誘導するための方法
WO2015035063A3 (fr) * 2013-09-05 2015-11-05 Sanford-Burnham Medical Research Institute Modulation des lymphocytes t (γδ)
US10759863B2 (en) 2013-09-05 2020-09-01 Sanford Burnham Prebys Medical Discovery Institute Modulation of γδ T cells
CN113105550A (zh) * 2014-04-10 2021-07-13 拉法医疗有限公司 结合人Vγ9Vδ2 T细胞受体的免疫球蛋白
CN107208061A (zh) * 2014-12-05 2017-09-26 伦敦国王学院 γδ T细胞扩增方法
JP2017537625A (ja) * 2014-12-05 2017-12-21 キングス カレッジ ロンドンＫｉｎｇｓ Ｃｏｌｌｅｇｅ Ｌｏｎｄｏｎ ガンマデルタｔ細胞増殖手順
US11566222B2 (en) 2014-12-05 2023-01-31 King's College London γδ T cell expansion procedure
US10557117B2 (en) 2014-12-05 2020-02-11 King's College London Gammadelta T cell expansion procedure
JP2019530470A (ja) * 2016-08-05 2019-10-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＦｏｘｐ３＋調節性Ｔ細胞のエクスビボ生成及びその治療的使用
WO2018024896A1 (fr) * 2016-08-05 2018-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) GÉNÉRATION EX VIVO DE LYMPHOCYTES T RÉGULATEURS γδ FOXP3+ ET UTILISATIONS THÉRAPEUTIQUES CORRESPONDANTES
US11198851B2 (en) 2016-10-28 2021-12-14 Inserm (Institut National De La Sante Et De La Rechere Medicale) Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof
US11384336B2 (en) 2016-12-07 2022-07-12 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory T cells
JP2022515791A (ja) * 2018-12-24 2022-02-22 ▲広▼▲東▼▲ジ▼▲徳▼康民生物科技有限▲責▼任公司 ヒトＶγ９Ｖδ２Ｔ細胞増殖培養方法及び培地
JP7295243B2 (ja) 2018-12-24 2023-06-20 ▲広▼▲東▼▲ジ▼▲徳▼康民生物科技有限▲責▼任公司 ヒトＶγ９Ｖδ２Ｔ細胞増殖培養方法及び培地

Also Published As

Publication number Publication date
ITRM20070437A1 (it) 2009-02-11

Similar Documents

Publication Publication Date Title
WO2009037723A1 (fr) Procédé pour la génération et l'expansion de lymphocytes t régulateurs gamma/delta, cellules ainsi obtenues et leurs utilisations
Li et al. New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+ CD4+ regulatory T cells
AU2008201685B2 (en) CD4+CD25+ regulatory T cells from human blood
US7122340B2 (en) Regulatory T cells; methods
AU2006232374B2 (en) Preventing rejection of transplanted tissue using regulatory T cells
JP6592551B2 (ja) 免疫調節活性を有する細胞集団、その調製方法、及び、その使用
US8603815B2 (en) CD4+ CD25− T cells and Tr1-like regulatory T cells
Pothoven et al. Rapamycin-conditioned donor dendritic cells differentiate CD4+ CD25+ Foxp3+ T cells in vitro with TGF-β1 for islet transplantation
Guo et al. In vitro-expanded CD4+ CD25highFoxp3+ regulatory T cells controls corneal allograft rejection
EP2820125A1 (fr) Expansion de lymphocytes t régulateurs réagissant avec des alloantigènes
JP4256431B2 (ja) 移植片−対−宿主疾患を抑制するサイトカイン、細胞およびマイトジェンの使用
Xia et al. Prevention of allograft rejection by amplification of Foxp3+ CD4+ CD25+ regulatory T cells
EP2859092B1 (fr) Vaccin thérapeutique pour le traitement du diabète de type 1 chez les enfants, application du trieur de cellules et procédé de multiplication des lymphocytes t régulateurs afin de produire un vaccin thérapeutique pour le traitement du diabète de type 1
JPH04325087A (ja) Ｃｄ４＋ヘルパーｔ細胞の産生方法
JP4435985B2 (ja) ＴｃＲγδＴ細胞の生産方法
Xu et al. IL-15 and dendritic cells induce proliferation of CD4+ CD25+ regulatory T cells from peripheral blood
US8323969B2 (en) Preparation of regulatory T cells using ICAM-1 co-stimulation
Zeng et al. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation
Merlo et al. Matured human monocyte-derived dendritic cells (MoDCs) induce expansion of CD4+ CD25+ FOXP3+ T cells lacking regulatory properties
WO2012160200A1 (fr) Cellules dendritiques tolérogènes et leur utilisation en thérapie cellulaire
JP7277255B2 (ja) インビトロでの制御性ｔ細胞の特異性評価方法
EP1391504A1 (fr) Cellules T CD4+ CD25- et cellules T régulatrices similaires aux cellules Tr1
Jin et al. Functional and phenotypic properties of peripheral T cells anergized by autologous CD3+ depleted bone marrow cells
JP2005514054A (ja) プロフェッショナルおよびサイトカイン産生制御ｔ細胞の誘導のための方法
EP1391210A2 (fr) Médicament régulateur comprenant des cellules T CD4+CD25 et des cellules Tr1-analogues régulatrices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831294

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831294

Country of ref document: EP

Kind code of ref document: A1